Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

Diabetes Care

Volumn 31, Issue 9, 2008, Pages 1816-1823

  Smith, Steve R ^a   Aronne, Louis J ^b   Burns, Colleen M ^c   Kesty, Nicole C ^c   Halseth, Amy E ^c   Weyer, Christian ^c  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAMLINTIDE; AMYLOID; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBESITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; BODY MASS; BODY SIZE; DRUG EFFECT; FOLLOW UP; LIFESTYLE; MIDDLE AGED; TIME;

ADULT; AMYLOID; BODY MASS INDEX; BODY SIZE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; MIDDLE AGED; PLACEBOS; SINGLE-BLIND METHOD; TIME FACTORS; WEIGHT LOSS;

EID: 56149124659     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0029     Document Type: Article

References (22)

1. Colman E: Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 143:380-385, 2005
2. Chen H, Roth J, Schroeder B, Weyer C: Role of ilet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy. Current Diabe-tesReviews 4:79-91, 2008
3. Kruger DF, Gloster MA: Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs 64:1419-1432, 2004
4. Lutz TA: Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets 6:181-189, 2005
5. RothJD, Hughes H, Kendall E, Baron AD, Anderson CM: Anti-obesity effects of the b-cell hormone amylin in diet induced obese rats: effects on food intake, body weight, composition, energy expenditure and gene expression. Endocrinology 147: 5855-5864, 2006
6. Mack CM, Wilson J, Athanacio J, Reynolds J, Laugero K, Guss S, Vu C, Roth J, Parkes D: Pharmacological Actions of the Peptide Hormone Amylin in the Long-Term Regulation of Food Intake, Food Preference and Body Weight. Am J Physiol Regul Integr Comp Physiol 293:R1855-R1863, 2007
7. ChapmanI, ParkerB, DoranS, Feinle-Bisset C, Wishart J, Strobel S, Wang Y, Burns C,Lush C, Weyer C, Horowitz M: Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 48:838-848, 2005
8. Smith SR, Blundell JE, Burns C, Ellero C, Schroeder BE, Kesty NC, Chen K, Halseth AE, Lush CW, Weyer C: Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 293:E620-E627, 2007
9. Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C: Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 92:2977-2983, 2007
10. Brownell KD: The LEARN Program for Weight Management. Dallas, TX, American Health Publishing Company, 2004
11. World Health Organization: Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity. Geneva, World Health Organization, 1998 (Tech. Rep. Ser., no. WHO/NUT/NCO/98.1)
12. Amylin Pharmaceuticals: SYMLIN Prescribing Information [article online], 2007. Available from www.SYMLIN.com.Accessed 8 February 2008
13. National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report [article online], 1998 (NIH publ. no. 98-4083). Available from http://www.ncbi.nlm.nih. gov/books/bookres.fcgi/obesity/obesity. pdf. Accessed 8 December 2005
14. Food and Drug Administration, Division of Metabolic and Endocrine Drug Products: Guidance for the clinical evaluation of weight-control drugs. Crit Rev Food Sci Nutr 41:91-99, 2001
15. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ: Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl JMed 353:2111-2120, 2005
16. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolter-man OG: Amylin replacement with pram-lintide as an adjunct to insulin therapy improves long-term glycaemic and weight controlinType 1 diabetes mellitus: A 1-year randomized controlled trial. Diabet Med 21:1204-1212, 2004
17. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26:784-790, 2003
18. Simons-Morton DG, Obarzanek E, Cutler JA: Obesity research-limitations of methods, measurements, and medications. JAMA 295:826-828, 2006
19. Roche: XENICAL Prescribing Information [article online], 2007. Available from http://www.rocheusa.com/products/xenical/pi.pdf. Accessed 1 May 2008
20. Smith IG, Goulder MA: Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 50:505-512, 2001
21. Roth JD, Mack C, Kesty NC, Parkes DG, Weyer C: Integrated neurohormonal ap-proaches to the treatment of obesity: the amylin agonist pramlintide and its interactions with leptin and PYY signaling pathways. In Handbook of Obesity: Clinical Applications. 3rd ed. New York, Informa Healthcare, 2008
22. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD: Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies. Proc Natl Acad SciUSA 105:7257-7262, 2008